Articles tagged #Itp on Vitalspell.
A 25-patient phase 1/2 trial published in Nature Medicine found that low-dose oral NMN was well tolerated in adults with steroid-refractory immune thrombocytopenia, with 20 percent meeting the primary platelet-response endpoint and 52 percent maintaining responses through week 8.
